Analysts Set BioAge Labs, Inc. (NASDAQ:BIOA) Price Target at $43.50

BioAge Labs, Inc. (NASDAQ:BIOA) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $43.50.

BIOA has been the subject of several analyst reports. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Roth Capital initiated coverage on shares of BioAge Labs in a research note on Wednesday, May 27th. They set a “buy” rating and a $36.00 price objective for the company. Needham & Company LLC began coverage on shares of BioAge Labs in a report on Friday, March 27th. They issued a “buy” rating and a $50.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday. Finally, BTIG Research started coverage on shares of BioAge Labs in a research report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target for the company.

BioAge Labs Stock Performance

Shares of NASDAQ:BIOA opened at $21.77 on Friday. The stock has a market capitalization of $967.68 million, a price-to-earnings ratio of -9.07 and a beta of 0.61. BioAge Labs has a 1-year low of $4.11 and a 1-year high of $25.95. The company has a 50 day moving average price of $20.26 and a 200 day moving average price of $19.32.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million for the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. On average, sell-side analysts expect that BioAge Labs will post -2.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BIOA. CWM LLC lifted its stake in BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after acquiring an additional 1,053 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of BioAge Labs in the 3rd quarter valued at about $27,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of BioAge Labs in the fourth quarter worth approximately $77,000. Nisa Investment Advisors LLC boosted its holdings in shares of BioAge Labs by 4,219.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock worth $135,000 after purchasing an additional 10,000 shares during the period. Finally, Bank of Nova Scotia acquired a new stake in shares of BioAge Labs during the first quarter worth approximately $180,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.